HYTN Innovations Inc. announced that it has successfully initiated cultivation of psilocybin mushrooms under its Dealer's License granted by Health Canada in accordance with the Controlled Drugs and Substances Act. This announcement is a significant development supporting HYTN's mission to be a leading manufacturer of psychoactive and psychotropic compounds. The company also announced it has installed equipment at its Kelowna facility, including high-performance liquid chromatography, and gas chromatography­mass spectrometry, to support the development of Active Pharmaceutical Ingredients (APIs) and strengthen the company's technological capabilities.

HYTN has also established a partnership with Graeme Staley, founder of Entheopharm Solutions Inc., and Dr. Philippe Henry, enabling the company to commence development of APIs containing a wide range of compounds, with the goal of positioning it as a leader in the emerging field of psychedelics.